NCT05568069 RCT of Implantable Defibrillators in Patients With Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 2,504 participants in total. It began in 2023-04-12 with a primary completion date of 2029-02-28.

Brief Summary

BRITISH is a UK multicentre trial of patients who have been diagnosed with heart failure due to Non-Ischemic Cardiomyopathy (NICM, or heart failure that is not caused by blocked heart arteries. Participants will be randomised into two groups. Half the participants will receive an Implantable Cardioverter-Defibrillator (ICD) and the other half will not. The aim of the study will be to compare all-cause mortality (death from any cause) between these two groups at 36 months, and longer-term to 10 years. The study has the potential to change international heart failure treatment guidelines and to improve how patients with this condition are managed.

Eligibility Criteria

Inclusion Criteria: 1. A diagnosis of NICM on contrast-enhanced cardiovascular magnetic resonance imaging 2. LV scar on routine CMR (patient without scar can enter the registry) 3. New York Heart Association (NYHA) Heart Failure (HF) functional class I-III and severely impaired left ventricular function (LVEF ≤ 35% on any imaging modality) after a minimum of 3 months of treatment with optimal medical therapy (OMT) as recommended by National Institute for Health and Care Excellence (NICE) 4. Able and willing to provide informed consent Exclusion Criteria: 1. New York Heart Association (NYHA) HF functional class IV after 3 months of optimal medical therapy (OMT) 2. Acute decompensated heart failure 3. Previous implantable device in situ (PPM, Cardiac Resynchronisation Therapy (CRT) or ICD) 4. Ischemic cardiomyopathy (ICM) is defined as segmental wall motion abnormalities or wall thinning in a particular coronary territory with subendocardial or transmural late gadolinium enhancement (LGE). Patients with an LVEF ≤35% and a small amount of ischemic LGE (i.e. an infarct out of keeping with the amount of LV dysfunction) will not be excluded (so-called dual pathology patients) 5. Known diagnosis of amyloidosis, sarcoidosis, arrhythmogenic right ventricular cardiomyopathy, or hypertrophic cardiomyopathy (diseases in which there are specific guidelines regarding defibrillator therapy) 6. Known Lamin gene mutation or a positive family history of a Lamin gene mutation 7. Valve disease is considered likely to require surgery during the 3 years follow-up period 8. Complex congenital heart disease 9. Any secondary prevention ICD indication 10. Heart transplant recipient or admitted for cardiac transplantation/ left ventricular assist device 11. Clinically apparent myocardial ischemia which requires revascularization 12. Intracardiac mass which requires surgery 13. Active endocarditis 14. Active Septicaemia 15. Pregnancy 16. Life expectancy \<2 years secondary to any other cause (i.e. malignancy) 17. Active treatment with chemotherapy 18. Severe renal failure (GFR \<30) 19. Actively participating in another study without prior agreement between both Chief Investigators

Contact & Investigator

Frequently Asked Questions

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.